Fig 2: IPO5 mediates RASAL2 nuclear transport by NLS a Putative NLS sequence segments of RASAL2 protein. b Immunofluorescence images exhibit the localizations of the exogenously expressed RASAL2 wild type and putative NLS mutant fused with HA in CRC cells. c The effect of WT and putative NLS mutant plasmid on the distribution of RASAL2 was tested by subcellular fractionation method in CRC cells. d The impact of NLS mutant on the interaction between RASAL2 and IPO5 was detected by CO-IP assays

Fig 3: Illustration of IPO5 involvement in CRC. IPO5 interacts with the NLS sequence of RASAL2 leading to RASAL2 nuclear transposition, This preventing RASAL2 from functioning as a RAS signaling pathway suppressor in the cytoplasm. Thus resulting in RAS signal activation and CRC growth and metastasis

Fig 4: RASAL2 represent novel IPO5 cargo protein a CO-IP technology was used to identify IPO5 interaction proteins. After silver staining, specific protein bands were collected and then identified by mass spectrometry (MS). b Evaluation of the biological processes of the putative IPO5 binding partners. Candidates were conducted on the pathway analysis with Cytoscape softwar and Wikipathway database. c Subcellular fractionation was performed to illustrate that RASAL2 is one of the cargos of IPO5. Data represent the mean ± SD of 3 independent experiments. *P < 0.05. d CO-IP assays was used to further validation the interaction between RASAL2 and IPO5. e Representative fluorescence images of the location change of RASAL2 in the cells knockdown or overexpress IPO5